[{"id":"df319938-99e5-4a75-bc4a-becf19647646","acronym":"","url":"https://clinicaltrials.gov/study/NCT02970539","created_at":"2021-01-18T14:36:05.005Z","updated_at":"2024-07-02T16:36:17.066Z","phase":"Phase 1b","brief_title":"Ph1b Study of Oraxol in Comb. w. Ramucirumab in Patients w. Gastric, Gastro-esophageal, or Esophageal Cancers","source_id_and_acronym":"NCT02970539","lead_sponsor":"Athenex, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Cyramza (ramucirumab) • Oraxol (oral paclitaxel/encequidar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 12/08/2016","start_date":" 12/08/2016","primary_txt":" Primary completion: 03/27/2019","primary_completion_date":" 03/27/2019","study_txt":" Completion: 12/31/2022","study_completion_date":" 12/31/2022","last_update_posted":"2022-02-16"}]